US2011243904A1PendingUtilityA1

Rna interference target for treating aids

Assignee: UNIV XIAMENPriority: May 31, 2007Filed: Jun 2, 2008Published: Oct 6, 2011
Est. expiryMay 31, 2027(~0.8 yrs left)· nominal 20-yr term from priority
C12N 2310/14C12N 2310/12A61P 31/18C12N 2310/11C12N 15/1132
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to RNA interference target sequence targeting HIV for the treatment of AIDS. Based on the target sequence, recombinant expression vectors, packaging vectors and cells were constructed, which express a siRNA and/or a miRNA and/or a ribozyme and/or an antisense oligonucleotide targeting HIV. Also provided is the use of the recombinant expression vectors, packaging vectors and recombinant cells in the manufacture of a medicament for the treatment of AIDS.

Claims

exact text as granted — not AI-modified
1 . A RNA interference target sequence targeting HIV, which is selected from:
 (1) a sequence set forth in any one of SEQ ID NOs:1-32, or   (2) a sequence that has at least 70%, preferably at least 80%, 85%, 90%, 95%, 98% or higher identity to the sequence defined in (1), or   (3) a nucleotide sequence that can hybridize with the sequence defined in (1) under stringent conditions or highly stringent conditions, or   (4) a nucleotide sequence that is different from the sequence defined in (1) by only 1-3, preferably 1-2, more preferably 1 nucleotide(s), or   (5) a fragment or a complementary sequence of any of the sequences referred to above.   
     
     
         2 . A nucleic acid construct or a vector, such as an expression vector, comprising the sequence according to  claim 1 . 
     
     
         3 . A siRNA or a miRNA or a ribozyme or an antisense oligonucleotide obtained based on the RNA interference target sequence according to  claim 1 , which can inhibit the expression of the corresponding gene of HIV and/or the replication of HIV and/or the infection of HIV. 
     
     
         4 . A recombinant expression vector which can express the siRNA or the miRNA or the ribozyme or the antisense oligonucleotide according to  claim 3 . 
     
     
         5 . The recombinant expression vector according to  claim 4 , comprising a nucleic acid sequence encoding the siRNA or the miRNA or the ribozyme or the antisense oligonucleotide targeting HIV, wherein the encoding nucleic acid sequence is operably linked to an expression controlling sequence so that the siRNA or the miRNA or the ribozyme or the antisense oligonucleotide can be expressed in an animal cell, especially a mammalian cell, such as a human cell, preferably a HIV receptor cell and a stem cell. 
     
     
         6 . The recombinant expression vector according to  claim 4 , which is a plasmid vector or a virus vector, such as a retrovirus vector, including a lentivirus vector. 
     
     
         7 . (canceled) 
     
     
         8 . An isolated cell transformed or transfected or transduced with the recombinant expression vector according to  claim 4 . 
     
     
         9 . (canceled) 
     
     
         10 . A modified cell, including an animal cell, such as a mammalian cell, preferably a human cell, preferably a HIV receptor cell and a stem cell, such as a CD4+cell and a CD34+cell, which can express or comprises the siRNA or the miRNA or the ribozyme or the antisense oligonucleotide according to  claim 3 . 
     
     
         11 . The modified cell according to  claim 10 , which carries in its genome or outside of its genome an encoding nucleic acid sequence comprising the RNA interference target sequence according to  claim 1 , wherein the encoding nucleic acid sequence is operably linked to an expression-controlling sequence so that the siRNA or the miRNA or the ribozyme or the antisense oligonucleotide can be expressed in the cell, including an animal cell, such as a mammalian cell, preferably a human cell, preferably a HIV receptor cell and a stem cell, such as a CD4+cell and a CD34+cell. 
     
     
         12 . A method for producing the cell according to any one of  claims 8  and  10 , comprising transforming or transfecting or transducing a cell, including an animal cell, such as a mammalian cell, preferably a human cell, preferably a HIV receptor cell and a stem cell, such as a CD4+cell and a CD34+cell, with the recombinant expression vector according to  claim 4 . 
     
     
         13 . A combination of DNA sequences comprising or consisting of a first DNA sequence encoding a sense RNA segment and a second DNA sequence encoding an antisense RNA segment, wherein the sense RNA segment comprises a RNA sequence encoded by the target sequence according to  claim 1 , and the antisense RNA segment can form a double-stranded RNA with the sense RNA segment, and wherein the double-stranded RNA can suppress the expression of HIV gene and/or the replication of HIV and/or infection of HIV. 
     
     
         14 . A small interference RNA (siRNA) comprising a sense RNA segment and an antisense RNA segment, wherein the sense RNA segment comprises a RNA sequence encoded by the target sequence according to  claim 1 , and the antisense RNA segment can form a double-stranded RNA with the sense RNA segment, and wherein the double-stranded RNA can suppress the expression of the corresponding gene of HIV and/or the replication of HIV and/or the infection of HIV. 
     
     
         15 . (canceled) 
     
     
         16 . A method for treating HIV infection or a HIV patient or inhibiting the replication or gene expression of HIV, comprising administering to a patient a therapeutically effective amount of:
 the RNA interference target sequence according to  claim 1 , or   the nucleic acid construct or the vector according to  claim 2 , or   the siRNA or the miRNA or the ribozyme or the antisense oligonucleotide according to  claim 3 , or   the recombinant expression vector according to  claim 4 , or   the cell according to any one of  claims 8  and  10 , or   the siRNA according to  claim 14 .   
     
     
         17 . (canceled) 
     
     
         18 . (canceled)

Join the waitlist — get patent alerts

Track US2011243904A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.